DURECT Corporation announced that its New Drug Application (NDA) for Remoxy was accepted by the FDA for the treatment of moderate to severe chronic pain.  This resubmitted NDA has a projected PDUFA goal date of June 23, 2011.

Remoxy is a controlled release formulation of oxycodone for moderate-to-severe chronic pain designed to reduce potential risks of unintended use.

For more information call (408) 777-1417 or visit www.durect.com.

Topics:

Narcotic Analgesics Pain Management